Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
131 hedge funds and large institutions have $254M invested in Catalyst Pharmaceutical in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 49 reducing their positions, and 19 closing their positions.
243% more call options, than puts
Call options by funds: $819K | Put options by funds: $239K
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
8% more capital invested
Capital invested by funds: $236M → $254M (+$18.3M)
2.78% more ownership
Funds ownership: 60.98% → 63.76% (+2.8%)
1% more funds holding
Funds holding: 130 → 131 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$11.5M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$5.94M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.31M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$4M |
| 5 |
Millennium Management
New York
|
+$3.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$7.18M |
| 2 |
Squarepoint
New York
|
-$3.11M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$3.04M |
| 4 |
Two Sigma Investments
New York
|
-$2.87M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.74M |
CPRX Hedge Fund Activity: Q1 2020 in Review
131 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2020, worth a combined $254M — up 7.8% from $236M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CPRX positions and 19 closed out — a net gain of 2 holders — while 44 added to existing stakes and 49 trimmed.
The largest buyer was Mangrove Partners, adding an estimated $11.5M. The largest seller was Nuveen, cutting an estimated $7.18M.
- 131 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2020, up from 130 in Q4 2019.
- Funds reported $254M of Catalyst Pharmaceutical stock for Q1 2020, up 7.8% quarter-over-quarter.
- 21 funds opened new Catalyst Pharmaceutical positions in Q1 2020 and 19 closed out, a net change of +2 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2020 was Mangrove Partners, an estimated $11.5M added.
- The largest Catalyst Pharmaceutical seller in Q1 2020 was Nuveen, an estimated $7.18M sold.
Based on aggregated 13F filings for Q1 2020.